Human PRTFDC1 Protein (His Tag)

Catalog Number: **14023-H07E**

General Information

Gene Name Synonym:

HHGP; PRTFDC1

Protein Construction:

A DNA sequence encoding the mature form of human PRTFDC1 (Q9NRG1-1) (Met1-Val225) was expressed with a polyhistide tag at the N-terminus.

Source: Human

Expression Host: E. coli

QC Testing

Purity: > 95 % as determined by SDS-PAGE

Endotoxin:

Please contact us for more information.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 ℃

Predicted N terminal: His

Molecular Mass:

The recombinant human PRTFDC1 consists of 240 amino acids and predicts a molecular mass of 27.5 KDa. It migrates as an approximately 19 KDa band in SDS-PAGE under reducing conditions.

Formulation:

Lyophilized from sterile 50mM Tris, 10% glycerol, pH 8.0

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:

Store it under sterile conditions at -20℃ to -80℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

PRTFDC1 is a member of the purine/pyrimidine phosphoribosyltransferase family. It can bind GMP, IMP and alpha-D-5-phosphoribosyl 1-pyrophosphate (PRPP). The epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis. PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse and has important implications for unraveling the molecular etiology of lesch-Nyhan disease(LND). LND is a severe X-linked neurological disorder caused by a deficiency of hypoxanthine phosphoribosyltransferase. PRTFDC1 has a low, barely measurable phosphoribosyltransferase activity (in vitro).

References

1.Welin M. et al., 2010, FEBS J. 277 (23): 4920-30. 2.Keebaugh AC. et al., 2011, PLoS One. 6 (7): e22381. 3.Suzuki E. et al., 2007, Oncogene. 26 (57): 7921-32.